[go: up one dir, main page]

NO20054668L - Aplidin for multippelt myelom-behandling - Google Patents

Aplidin for multippelt myelom-behandling

Info

Publication number
NO20054668L
NO20054668L NO20054668A NO20054668A NO20054668L NO 20054668 L NO20054668 L NO 20054668L NO 20054668 A NO20054668 A NO 20054668A NO 20054668 A NO20054668 A NO 20054668A NO 20054668 L NO20054668 L NO 20054668L
Authority
NO
Norway
Prior art keywords
aplidine
multiple myeloma
myeloma treatment
treatment
medicament
Prior art date
Application number
NO20054668A
Other languages
English (en)
Other versions
NO334264B1 (no
Inventor
Glynn Thomas Faircloth
Joseph R Bertino
Daniel Medina
Constantine S Mitsiades
Kenneth Anderson
Nicholas Mitsiades
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of NO20054668L publication Critical patent/NO20054668L/no
Publication of NO334264B1 publication Critical patent/NO334264B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Aplidin og aplidin-analoger blir anvendt ved fremstilling av et medikament for behandling av multippelt myelom.
NO20054668A 2003-03-12 2005-10-11 Anvendelse av aplidin ved fremstilling av et medikament for behandling av multippelt myelom NO334264B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45412503P 2003-03-12 2003-03-12
US52029303P 2003-11-14 2003-11-14
PCT/GB2004/001062 WO2004080477A1 (en) 2003-03-12 2004-03-12 Aplidine for multiple myeloma treatment

Publications (2)

Publication Number Publication Date
NO20054668L true NO20054668L (no) 2005-10-11
NO334264B1 NO334264B1 (no) 2014-01-20

Family

ID=32994545

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054668A NO334264B1 (no) 2003-03-12 2005-10-11 Anvendelse av aplidin ved fremstilling av et medikament for behandling av multippelt myelom

Country Status (20)

Country Link
US (1) US7381703B2 (no)
EP (1) EP1603584B1 (no)
JP (1) JP4584245B2 (no)
KR (1) KR101160320B1 (no)
AT (1) ATE406171T1 (no)
AU (1) AU2004218883B2 (no)
CA (1) CA2519789C (no)
CY (1) CY1108599T1 (no)
DE (1) DE602004016126D1 (no)
DK (1) DK1603584T3 (no)
ES (1) ES2312979T3 (no)
IL (1) IL170136A (no)
MX (1) MXPA05009742A (no)
NO (1) NO334264B1 (no)
NZ (1) NZ541611A (no)
PL (1) PL1603584T3 (no)
PT (1) PT1603584E (no)
RU (1) RU2335294C2 (no)
SI (1) SI1603584T1 (no)
WO (1) WO2004080477A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780417B2 (en) * 1999-11-15 2005-03-17 Pharma Mar S.A. Aplidine treatment of cancers
WO2004080421A2 (en) * 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
EP1942944A2 (en) * 2005-10-31 2008-07-16 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
RS54928B1 (sr) * 2006-02-28 2016-10-31 Pharma Mar Sa Poboljšano lečenje multiplog mijeloma
WO2008080956A1 (en) * 2006-12-29 2008-07-10 Pharma Mar, S.A. Prognostic molecular markers for the cancer therapy with aplidine
WO2009002553A1 (en) * 2007-06-25 2008-12-31 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
JP2011500650A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
WO2009111698A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved anticancer treatments
US8435992B2 (en) * 2008-05-16 2013-05-07 Pharma Mar S.A. Multiple myeloma treatments
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
EP0739210B1 (en) * 1993-12-29 2002-07-24 Matrix Pharmaceutical, Inc. Compositions for local delivery of cytostatic agents
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
AU3353897A (en) 1996-07-03 1998-02-02 Mckechnie Uk Limited Container
ATE321773T1 (de) 1996-10-24 2006-04-15 Univ Illinois Semisynthetisches verfahren zur herstellung von didemninanalogen
DK0956033T3 (da) 1996-10-24 2003-10-06 Univ Illinois Totalsyntese af amino-Hip-analogen af didemnin A
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
CA2288639A1 (en) * 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
AU764807B2 (en) * 1998-07-30 2003-08-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
AU781897B2 (en) 1999-05-25 2005-06-23 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU780417B2 (en) 1999-11-15 2005-03-17 Pharma Mar S.A. Aplidine treatment of cancers
RU2323000C2 (ru) 2000-04-07 2008-04-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Аналоги тамандарина и дидемнина и способы их получения и применения
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
WO2002028902A2 (en) * 2000-10-05 2002-04-11 Immunex Corporation Nectin polypeptides, polynucleotides, methods of making and use thereof
MXPA03003230A (es) * 2000-10-12 2004-12-03 Pharma Mar Sa Tratamiento de canceres.
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
AU2002219472A1 (en) * 2001-01-02 2002-07-16 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
PT1435991E (pt) 2001-10-19 2009-01-16 Pharma Mar Sa Utilização de aplidina para o tratamento de cancro pancreático
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
ES2312979T3 (es) 2009-03-01
SI1603584T1 (sl) 2009-02-28
KR101160320B1 (ko) 2012-06-26
DK1603584T3 (da) 2009-01-05
US20070149445A9 (en) 2007-06-28
PT1603584E (pt) 2008-11-21
AU2004218883A1 (en) 2004-09-23
IL170136A (en) 2014-04-30
KR20060006779A (ko) 2006-01-19
DE602004016126D1 (de) 2008-10-09
US20060172926A1 (en) 2006-08-03
NZ541611A (en) 2008-04-30
WO2004080477A1 (en) 2004-09-23
MXPA05009742A (es) 2006-05-25
WO2004080477A8 (en) 2004-11-11
RU2005131578A (ru) 2006-01-27
JP2006519828A (ja) 2006-08-31
RU2335294C2 (ru) 2008-10-10
EP1603584A1 (en) 2005-12-14
CA2519789A1 (en) 2004-09-23
ATE406171T1 (de) 2008-09-15
NO334264B1 (no) 2014-01-20
AU2004218883B2 (en) 2009-10-01
JP4584245B2 (ja) 2010-11-17
CA2519789C (en) 2012-07-03
CY1108599T1 (el) 2014-04-09
EP1603584B1 (en) 2008-08-27
US7381703B2 (en) 2008-06-03
PL1603584T3 (pl) 2009-02-27

Similar Documents

Publication Publication Date Title
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
ATE461217T1 (de) Glp-1-verbindungen
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
MY151032A (en) Treatment of tnf? related disorders
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
RS54928B1 (sr) Poboljšano lečenje multiplog mijeloma
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
MY135829A (en) Analeptic and drug combinations
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
NO20053947D0 (no) Forbedrede antitumorale behandlinger.
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
SE0301650D0 (sv) Novel compounds
PL377176A1 (pl) N-Sulfonylo-4-metylenoamino-3-hydroksy-2-pirydony
IS7825A (is) Meðferðarfræðileg meðhöndlun
DE502005007472D1 (de) Desoxo-nonadepsipeptide
DK1537132T3 (da) Salt af mortin-6-glucuronid
ATE428418T1 (de) Mit einem serotonin-transporter zusammenwirkende mittel zur krebsbehandlung
DE50309647D1 (de) Ng fibrotischer erkrankungen
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
MX2022001853A (es) Injerto gingival.
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs